
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
The Tufts Center for Drug Development found in a recent analysis that the pharmaceutical industry is adopting artificial intelligence (AI) in numerous ways. 59% of respondents said they plan to expand artificial intelligence staff through 2020. The highest uses of AI are in clinical operations, safety/risk management, and information technology.
For more from the report, click






